CL2021000440A1 - The use of alpha-2-adrenergic receptor agonists to improve vision. - Google Patents

The use of alpha-2-adrenergic receptor agonists to improve vision.

Info

Publication number
CL2021000440A1
CL2021000440A1 CL2021000440A CL2021000440A CL2021000440A1 CL 2021000440 A1 CL2021000440 A1 CL 2021000440A1 CL 2021000440 A CL2021000440 A CL 2021000440A CL 2021000440 A CL2021000440 A CL 2021000440A CL 2021000440 A1 CL2021000440 A1 CL 2021000440A1
Authority
CL
Chile
Prior art keywords
alpha
adrenergic receptor
improve vision
receptor agonists
visual
Prior art date
Application number
CL2021000440A
Other languages
Spanish (es)
Inventor
Mohammed Dibas
Daniel W Gil
Wayne Chen
Miguel Alcantara
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2021000440A1 publication Critical patent/CL2021000440A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen métodos para usar el agonista del receptor alfa-2-adrenérgico de Fórmula I para mejorar la visión tal como en el tratamiento de condiciones oculares tales como presbicia, mala visión nocturna, encandilamiento visual, destellos visuales, halos visuales y algunas formas de miopía (por ejemplo, miopía nocturna).Methods are described for using the Formula I alpha-2-adrenergic receptor agonist to improve vision such as in the treatment of eye conditions such as presbyopia, poor night vision, visual glare, visual flashes, visual halos and some forms of myopia. (for example, night myopia).

CL2021000440A 2018-08-21 2021-02-22 The use of alpha-2-adrenergic receptor agonists to improve vision. CL2021000440A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862720671P 2018-08-21 2018-08-21

Publications (1)

Publication Number Publication Date
CL2021000440A1 true CL2021000440A1 (en) 2021-09-20

Family

ID=67841225

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000440A CL2021000440A1 (en) 2018-08-21 2021-02-22 The use of alpha-2-adrenergic receptor agonists to improve vision.

Country Status (17)

Country Link
US (3) US20210205273A1 (en)
EP (1) EP3840750A1 (en)
JP (1) JP2021534217A (en)
KR (1) KR20210047323A (en)
CN (1) CN112823003A (en)
AR (1) AR115991A1 (en)
AU (1) AU2019325486A1 (en)
BR (1) BR112021003295A2 (en)
CA (1) CA3110318A1 (en)
CL (1) CL2021000440A1 (en)
CO (1) CO2021003460A2 (en)
IL (1) IL280990A (en)
MX (1) MX2021002112A (en)
PH (1) PH12021550372A1 (en)
SG (1) SG11202101730SA (en)
TW (1) TW202021584A (en)
WO (1) WO2020041340A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021168349A1 (en) * 2020-02-20 2021-08-26 Allergan, Inc. Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
EP2525776B1 (en) 2010-01-22 2015-10-28 Allergan, Inc. Intracameral sustained release therapeutic agent implants
US10507245B2 (en) * 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
TWI631961B (en) 2013-03-15 2018-08-11 美商歐樂根公司 Prostamide-containing intraocular implant
CA2907881A1 (en) 2013-03-27 2014-10-02 Forsight Vision5, Inc. Bimatoprost ocular silicone inserts and methods of use thereof
WO2014165308A2 (en) 2013-04-01 2014-10-09 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US11077053B2 (en) * 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia

Also Published As

Publication number Publication date
PH12021550372A1 (en) 2021-11-29
BR112021003295A2 (en) 2021-05-18
US20220160623A1 (en) 2022-05-26
EP3840750A1 (en) 2021-06-30
CN112823003A (en) 2021-05-18
IL280990A (en) 2021-04-29
AR115991A1 (en) 2021-03-17
US20210205273A1 (en) 2021-07-08
SG11202101730SA (en) 2021-03-30
JP2021534217A (en) 2021-12-09
US20220288031A1 (en) 2022-09-15
CA3110318A1 (en) 2020-02-27
CO2021003460A2 (en) 2021-04-08
TW202021584A (en) 2020-06-16
MX2021002112A (en) 2021-07-16
KR20210047323A (en) 2021-04-29
AU2019325486A1 (en) 2021-03-25
WO2020041340A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
CO2020016619A2 (en) Bispecific anti-pvrig / anti-tigit antibodies and methods of use
CR20180594A (en) GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF
CR20160501A (en) USEFUL QUINOXALINE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEIVER (FGFR) CINASA SHOCK ABSORBERS
DOP2020000040A (en) SPIROCYCLICAL COMPOUNDS AND THEIR METHODS OF PREPARATION AND USE
UY35258A (en) ANTI-PDGFR-beta ANTIBODIES AND USES OF THE SAME
CL2015002546A1 (en) Substituted 3-phenylpropylamine derivatives for the treatment of diseases and ophthalmic disorders
CO2017002506A2 (en) New activators of soluble guanylate cyclase and their use
GT201600091A (en) DERIVATIVES OF PURINA 2, 6-SUBSTITUTES AND ITS USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS
CL2017002913A1 (en) Treatment of postbariatric hypoglycemia with exendin (9-39)
ECSP20013337A (en) SPIROCYCLICAL COMPOUNDS AND THEIR PREPARATION AND USE METHODS
EA201791005A1 (en) IMPROVED ANTIBODIES AGAINST IL-6
ECSP21077614A (en) 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE COMPOUNDS
CL2015003195A1 (en) Purine derivatives as cb2 receptor agonists.
CL2020002774A1 (en) Combined treatment of ocular fibrosis and / or angiogenesis
CL2014002918A1 (en) Derivatives of spiro [2.4] fluorinated bridged heptane; Pharmaceutical composition and use as alx receptor agonists in the treatment of inflammatory, allergic diseases. cardiovascular, among others.
PE20171619A1 (en) METHOD TO PREVENT OR TREAT HEARING LOSS
MX2021013447A (en) Compositions and methods for treatment of ocular diseases.
CL2021000440A1 (en) The use of alpha-2-adrenergic receptor agonists to improve vision.
CR20130094A (en) ADENOSINE A1 AGONISTS FOR THE TREATMENT OF GLAUCOMA AND EYE HYPERTENSION
ECSP21002804A (en) SOLUBILIZED APIRASES, METHODS AND USES
EA201990752A1 (en) OPHTHALMOLOGICAL COMPOSITION CONTAINING CITYCOLINE PORTABLE BY LIPOSOMA FOR TREATMENT OF GLAUCOMA
AR119681A1 (en) METHODS OF TREATMENT OF BREAST CANCER WITH TUCATINIB
CO2020004075A2 (en) Monoclonal anti-trkb antibodies and methods of use
CL2022000522A1 (en) Lurbinectedin in the treatment of malignant mesothelioma.
BR112022016730A2 (en) PHARMACEUTICAL COMPOSITIONS OF ALPHA-2-ADRENERGIC RECEPTOR AGONISTS AND THEIR USE TO IMPROVE VISION